$0.80
+0.00 (+0.11%)
Open$0.82
Previous Close$0.80
Day High$0.82
Day Low$0.80
52W High$3.68
52W Low$0.68
Volume—
Avg Volume412.0K
Market Cap9.50M
P/E Ratio—
EPS$-0.34
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+2,935.0% upside
Current
$0.80
$0.80
Target
$24.31
$24.31
$15.00
$24.31 avg
$29.94
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 304.0K | 1.99M | 1.82M |
| Net Income | -3,724,821 | -271,887 | -219,394 |
| Profit Margin | -1,227.1% | -13.7% | -12.0% |
| EBITDA | -3,363,018 | -443,981 | -374,843 |
| Free Cash Flow | — | -242,138 | -341,295 |
| Rev Growth | — | +6.4% | +1.5% |
| Debt/Equity | 0.07 | 0.27 | 0.23 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $249.68 | -0.45% | 118.6 | 430.95B |
| AMGN | Amgen Inc | $412.84 | -1.20% | 25.1 | 219.39B |
| GILD | Gilead Sciences Inc | $138.12 | -0.01% | — | 165.85B |
| VRTX | Vertex Pharmaceuticals Inc | $508.33 | -1.57% | 28.3 | 124.51B |
| REGN | Regeneron Pharmaceuticals | $803.64 | -0.29% | 18.4 | 79.53B |
| ALNY | Alnylam Pharmaceuticals Inc | $227.29 | +0.07% | 35.2 | 28.41B |